Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8046848 | 0.89 | KMT2A (0.46) | KMT2ASLC6A2SLC6A3TDP1SLC1A1 | |
| SCHEMBL8256163 | 0.89 | KMT2A (0.46) | KMT2ASLC6A2SLC6A3TDP1SLC1A1 | |
| SCHEMBL8695483 | 0.87 | ALDH1A1 (0.51) | KMT2ASLC6A2SLC6A3TDP1SLC1A1 | |
| SCHEMBL23978728 | 0.85 | BCAT2 (0.49) | KMT2ASLC6A2SLC6A3TDP1SLC1A1 | |
| SCHEMBL29398484 | 0.85 | SLC1A3 (0.58) | KMT2ASLC6A2SLC6A3TDP1SLC1A1 | |
| SCHEMBL218262 | 0.82 | ALDH1A1 (0.53) | KMT2ASLC6A2SLC6A3TDP1SLC1A1 | |
| SCHEMBL22535897 | 0.82 | ALDH1A1 (0.53) | KMT2ASLC6A2SLC6A3TDP1SLC1A1 | |
| SCHEMBL22535886 | 0.82 | ALDH1A1 (0.53) | KMT2ASLC6A2SLC6A3TDP1SLC1A1 | |
| SCHEMBL218263 | 0.82 | ALDH1A1 (0.53) | KMT2ASLC6A2SLC6A3TDP1SLC1A1 | |
| SCHEMBL73708 | 0.82 | SLC7A5 (0.63) | KMT2ASLC6A2SLC6A3TDP1SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7211241-B2 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | SCHERING AKTIENGESELLSCHAFT (DE) | 2007-05-01 | — | — | US | disclosed |
| US-6861043-B2 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | SCHERING AG (DE) | 2005-03-01 | — | — | US | disclosed |
| US-20040091426-A1 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-05-13 | — | — | US | disclosed |
| EP-0768898-B1 | CASCADE-POLYMER COMPLEXES AND METHODS OF PRODUCING THE SAME | SCHERING AG (DE) | 2003-04-09 | — | — | EP | disclosed |
| US-20020187101-A1 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | SCHERING AG (DE) | 2002-12-12 | — | — | US | disclosed |
| US-6426059-B1 | NUCLEAR MAGNETIC RESONANCE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2002-07-30 | — | — | US | disclosed |
| US-6248306-B1 | MEDICAL DIAGNOSIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2001-06-19 | — | — | US | disclosed |
| US-6177060-B1 | NMR OR X-RAY LYMPHOGRAPHY IMAGES | SCHERING AKTIENGESEUSCHAFT (DE) | 2001-01-23 | — | — | US | disclosed |
| US-6166200-A | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-12-26 | — | — | US | disclosed |
| US-6063361-A | ADMINISTERING TO A PATIENT AT LEAST ONE CASCADE POLYMER COMPLEX AND SUBJECTING THE PATIENT TO A RADIOLOGY DIAGNOSIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-05-16 | — | — | US | disclosed |
| US-5919433-A | NUCLEAR MAGNETIC RESONANCE | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-07-06 | — | — | US | disclosed |
| US-5820849-A | DIAGNOSIS WITH NUCLEAR MAGNETIC RESONANCE | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-10-13 | — | — | US | disclosed |
| EP-0832150-A1 | CASCADE POLYMERS WITH IODINE-CONTAINING AROMATIC COMPOUNDS | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-04-01 | — | — | EP | disclosed |
| EP-0768898-A1 | CASCADE-POLYMER COMPLEXES AND METHODS OF PRODUCING THE SAME | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-04-23 | — | — | EP | disclosed |
| WO-1996041830-A1 | CASCADE POLYMERS WITH IODINE-CONTAINING AROMATIC COMPOUNDS | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-12-27 | — | — | WO | disclosed |
| WO-1996001655-A1 | CASCADE-POLYMER COMPLEXES AND METHODS OF PRODUCING THE SAME | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040091426-A1 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | ZYX, CCNY, MOK | KMT2A 1168/4885SLC6A2 4480/4885SLC6A3 4599/4885 |
| US-20020187101-A1 | Cascade polymer complexes, process for their production and pharmaceutical agents containing said complexes | TFPI, LYN, SYK | KMT2A 4826/4885SLC6A2 4817/4885SLC6A3 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.